Skip to content

Achillion blood disorder treatment shows promise

August 9, 2017

Shares of Achillion Pharmaceuticals Inc. ACHN, +29.70% surged in the extended session Tuesday after the drug developer met expectations for second-quarter results and said early results of a blood disorder treatment look promising. Achillion shares rallied 33% to $5.35 after hours. The company said four patients so far enrolled in a mid-stage clinical study of ACH-4471, meant to treat paroxysmal nocturnal hemoglobinuria, were responding well to the drug. Paroxysmal nocturnal hemoglobinuria is a rare, acquired condition where the body’s immune system destroys red blood cells in error. Achillion also reported a second-quarter loss of $22.5 million, or 16 cents a share, compared with a loss of $18.5 million, or 14 cents a share, in the year-ago period. Analysts surveyed by FactSet had forecast a loss of 16 cents a share.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: